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Aims: Chemotherapy-induced peripheral neuropathy (PN) is a treatment limiting
toxicity of paclitaxel. We evaluated if EPHA genetic variation (EPHA4, EPHA5, EPHA6,
and EPHA8) is associated with PN sensitivity by accounting for variability in systemic
paclitaxel exposure (time above threshold).
Methods: Germline DNA from 60 patients with breast cancer was sequenced. PN
was measured using the 8-item sensory subscale (CIPN8) of the patient-reported
CIPN20. Associations for 3 genetic models were tested by incorporating genetics
into previously published PN prediction models integrating measured paclitaxel
exposure and cumulative treatment. Significant associations were then tested for
association with PN-related treatment disruption.
Results: EPHA5 rs7349683 (minor allele frequency = 0.32) was associated with
increased PN sensitivity (β-coefficient = 0.39, 95% confidence interval 0.11–0.67,
p = 0.007). Setting a maximum tolerable threshold of CIPN8 = 30, optimal paclitaxel
exposure target is shorter for rs7349683 homozygous (11.6 h) than heterozygous
(12.6 h) or wild-type (13.6 h) patients. Total number of missense variants (median = 0,
range 0–2) was associated with decreased PN sensitivity (β-coefficient: −0.42, 95%
confidence interval −0.72 to −0.12, P = .006). No association with treatment disrup-
tion was detected for the total number of missense variants or rs7349683.
Conclusion: Isolating toxicity sensitivity by accounting for exposure is a novel
approach, and rs7349683 represents a promising marker for PN sensitivity that may
be used to individualize paclitaxel treatment.
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1 | INTRODUCTION
Paclitaxel is commonly used to treat early breast cancer and
improves overall survival in this treatment setting1. Weekly pacli-
taxel used in early breast cancer is similarly efficacious to every
2-week or every 3-week regimens2,3. Although it is highly effica-
cious, weekly paclitaxel has a dose-limiting toxicity, paclitaxel-
induced peripheral neuropathy (PN), which is characterized by
numbness, tingling, and pain in the hands and feet that can nega-
tively impact long-term quality of life4. Paclitaxel-induced PN
necessitates dosing delays, decreases, or even premature treatment
discontinuation5. These treatment disruptions decrease therapy
effectiveness6,7. Consequently, there is substantial interest in iden-
tifying patient-specific predictors of PN that could be used to indi-
vidualize paclitaxel therapy to prevent PN-necessitated treatment
disruptions and improve treatment efficacy.
Paclitaxel exposure (i.e. the amount of time paclitaxel systemic
concentrations remain above a threshold plasma concentration of
0.05 μM) is an established predictor of PN8-11. Individualized pacli-
taxel dosing to achieve a target exposure substantially decreases the
occurrence of PN, but some patients experience severe PN despite
receiving treatment at the target exposure10, suggesting these
patients have an inherent predisposition to PN (i.e. PN sensitivity). PN
sensitivity is probably determined by a combination of genetic and
clinical factors. These PN-sensitivity biomarkers could be discovered
by conducting analyses that account for exposure variability, which
would isolate the PN sensitivity phenotype.
Previous research has attempted to discover genetic predictors of
paclitaxel-induced PN12-14 or replicate previous findings15-17. These
important discoveries need to be fully validated to establish clinical
utility. Pioneering studies exploring these associations mostly utilized
a case–control approach with the endpoint of occurrence of PN18.
More recent studies have explored PN susceptibility by accounting
for the cumulative dose at PN occurrence12,13,19,20. Within these
studies, variants in genes encoding ephrin (EPHA) receptors from the
receptor tyrosine kinase family, which have a role in neuronal devel-
opment21, have been observed to increase risk of paclitaxel-induced
PN (i.e. EPHA4 rs17348202, EPHA5 rs7349683, EPHA6
rs301927)12,15-17,19,22. However, replication has been challenging,
probably because genetic variants should be considered alongside
other predictive variables when explaining the multifactorial PN end-
point. A recent study attempted to impute exposure from dosing
data23, but no prior analyses have incorporated measured paclitaxel
exposure to isolate PN sensitivity. Accounting for actual cumulative
exposure at PN occurrence is a novel approach to isolate PN sensitiv-
ity for use as a phenotype for PN biomarker discovery and validation.
We previously created models that explain the trajectory of
patient-reported PN during paclitaxel treatment using cumulative
treatment and measured paclitaxel exposure11. Clinical factors associ-
ated with PN were previously explored in this cohort11. The purpose
of this study is to utilize these previously published models to deter-
mine whether genetic variation in EPHA genes are associated with
increased PN sensitivity.
2 | METHODS
2.1 | Patient population and clinical data
Patients aged >18 years without PN or prior neurotoxic chemother-
apy scheduled to receive 12 weekly infusions of paclitaxel 80 mg/m2
for curative treatment of breast cancer were enrolled in a prospective,
observational clinical cohort registry (UMCCC 2014.002,
NCT0233815). Detailed information about these patients, their treat-
ment, pharmacokinetic sampling time points, PN data collection, and
the primary analysis of the association between pharmacokinetics and
PN severity have been previously reported and are described briefly
below11. All patients included in this study signed written informed
consent. This study was approved by the University of Michigan
IRBMed and was conducted in accordance with recognized ethical
guidelines.
2.2 | Pharmacokinetic sampling
Blood samples were collected 16–24 h after the start of the first pacli-
taxel infusion. Plasma samples were stored at −20C until measure-
ment of paclitaxel in plasma via liquid chromatography–mass
spectrometry. A previously published population-pharmacokinetic
model was used to estimate each patient's paclitaxel time above
threshold (Tc > 0.05), defined as the amount of time in h that the
patient's plasma concentration remains above 0.05 μM, utilizing the
What is already known about this subject
• Peripheral neuropathy (PN) is a treatment limiting
adverse effect of paclitaxel that is determined primarily
by drug exposure.
• Replication has been a challenge for genetic predictors of
paclitaxel-induced PN, including EPHA variants.
• Accounting for pharmacokinetic variability could isolate
genetic PN predisposition (i.e. PN sensitivity) for genetic
replication studies.
What this study adds
• This study supports EPHA5 rs7349683 as a biomarker of
PN sensitivity.
• rs7349683 may be utilized to estimate the optimal pacli-
taxel exposure target for individual patients, preventing
toxicity and improving treatment outcomes.
• Isolating toxicity sensitivity by accounting for drug expo-
sure is a novel analytical approach for pharmacogenetic
discovery and replication.
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measured paclitaxel concentration and the amount of time since the
beginning of infusion24,25.
2.3 | PN measurement
PN was quantified utilizing the Quality of Life Questionnaire
Chemotherapy-Induced Peripheral Neuropathy (CIPN20) from the
European Organisation for Research and Treatment of Cancer.
Patients completed the CIPN20 prior to their first paclitaxel dose
and weekly until the end of treatment. Since paclitaxel primarily
causes sensory PN, this analysis used the 8 sensory items of the
CIPN20 (CIPN8), excluding the ototoxicity question, as was
reported in the primary analysis of this cohort26,27. CIPN8 raw
scores were linearly translated to a 0–100 scale, with higher
scores representing greater PN, as recommended by the European
Organisation for Research and Treatment of Cancer scoring
manual 28.
2.4 | Pharmacogenomic sampling and DNA
isolation
A 5 mL whole blood sample was collected prior to the first cycle in a
lavender-top EDTA tube and stored at −20C. Germline DNA was
isolated from buffy coat using QIAamp DNA Mini Kits using the spin
protocol with manufacturer's instructions (QIAGEN, Valencia, CA,
USA). Sample quantity and quality was assessed using a NanoDrop
1000 spectrophotometer (Thermo Fisher Scientific Inc., Waltham,
MA, USA).
2.5 | Genotyping and single nucleotide variant
functional assessment
DNA sequencing techniques have been previously described in
detail29. Briefly, targeted exon sequencing was conducted for
chemotherapy-induced PN genes and genes previously associated
with PN. The isolated DNA was sheared and subjected to end
repair with target fragment size of 300–400 base pairs. It was
sequenced twice and sequencing reads were aligned to a reference
genome (grch37). Single nucleotide variants were ranked by variant
quality score recalibration according to the variant quality log-odds,
and only single nucleotide variants that had a specificity of >99.9%
and sensitivity of >90% were included. The annotations
included are based on Ensemble GRCh37.75. Posthoc verification
of rs7349683 genotype calls in sequencing data was
conducted via TaqMan allelic discrimination assay, as previously
described30.
This primary analysis of genetic PN predisposition was conducted
using only the sequencing data from the 4 EPHA genes (EPHA4,
EPHA5, EPHA6, EPHA8). The variants were categorized based on
predicted consequence on the encoded protein. Coding variants
include all variants (missense and synonymous) located in the trans-
lated region of DNA. Predicted functional consequence of variants
was determined by 2 different bioinformatics tools: CADD31,32 and
PROVEAN33. For coding variants, CADD PHRED-like scaled C-score
rankings ≥15 and PROVEAN scores <−2.5 were considered function-
ally consequential.
2.6 | Posthoc exploration of variants in linkage
disequilibrium
All positive associations were further explored using HaploReg for
variants in linkage disequilibrium (LD) using the American population
for the 1000G Phase 1 population for the LD calculation34. The LD
threshold was set at 0.8, and the variant position was described
relative to GENCODE genes. Variants found to be in LD were
explored using the previously described bioinformatics tools for cod-
ing variants. Each variant was also explored using GTex to determine
if it is an expression quantitative trait locus (P < .005) in neuron-
related tissues (brain or tibial nerve)35.
2.7 | Statistical analyses
The analysis was conducted by testing whether EPHA genetics signifi-
cantly contribute to a previously developed CIPN8 prediction model.
The base model from our prior publication included baseline CIPN8
(0–100), cumulative dose (mg/m2, actual-weight body surface area
adjusted), and relative dose intensity (defined as the proportion of
cumulative planned doses received to expected cumulative dose, in
order to account for delays and decreases)11. An interaction term
with Tc > 0.05 and cumulative dose was included based on our previous
findings that CIPN8 increased more quickly with continued dosing in
patients with longer Tc > 0.05. This PN sensitivity model, which incor-
porates paclitaxel exposure (Tc > 0.05), allows for direct testing of
genetic associations with the isolated phenotype of PN sensitivity.
The association between PN sensitivity and 3 different EPHA
genetic predictors were analysed independently: (i) missense variants:
the total number of missense variants per patient; (ii) functionally
consequential coding variants: the total number of coding variants
per patient predicted to be of functional consequence; and
(iii) rs7349683: the additive genetic effect of rs7349683, which was
selected for independent inclusion based on multiple prior reports of
its association with PN12,16,19.
Genetic predictors that were significantly associated with PN sen-
sitivity were then tested for an association with the clinically relevant
endpoint of sensitivity to PN-induced treatment disruption
(i.e. paclitaxel dose decrease, dose delay, or discontinuation due to
PN, as previously defined), using our previously published predictive
model that includes baseline CIPN8, cumulative dose, and Tc > 0.05
without an interaction term11. A posthoc analysis testing rs7349683 in
a dominant genetic model was conducted to affirm an additive model
best represents the genetic consequence of rs7349683.
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As a posthoc analysis, the predicted CIPN8 at the end of stan-
dard, undisrupted treatment (weekly dose = 80 mg/m2, number of
doses = 12, relative dose intensity = 1) was estimated for a typical
patient (baseline CIPN8 = 0) with each rs7349683 genotype (wild-
type, heterozygous, homozygous variant) and a range of paclitaxel
exposures (Tc > 0.05) of 0–16 h. These model results were then
used to identify the optimal exposure (Tc > 0.05) at which a patient
with each genotype would experience a maximum CIPN8 score of
10, 20, 30 or 40.
3 | NOMENCLATURE OF TARGETS AND
LIGANDS
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to
PHARMACOLOGY.
4 | RESULTS
4.1 | Patient demographics, pharmacokinetics and
genetics
Sixty patients were enrolled in this prospective cohort study. One
patient who received a 3-h paclitaxel infusion was excluded and time
above threshold (Tc > 0.05, defined as the amount of time in h that the
patient's plasma concentration remains above 0.05 μM) could not be
calculated for 1 patient (Figure 1). Patients included in this analysis
had a mean age of 52.5 years (range: 28–71, Table 1), had mean body
surface area of 1.83 m2 (standard deviation [SD:] 0.21) and the major-
ity (93.1%) were Caucasian. The average Tc > 0.05 was 10.72 h (SD:
2.73). As previously reported, CIPN8 was low at baseline (mean = 1.29,
SD = 3.04) and increased throughout treatment (mean maximum
CIPN8 = 13.26, SD = 1.76). Detailed patient demographics and CIPN8
data have been previously described11.
The 32 coding variants detected are included in Appendix A with
the results of the in silico prediction tools and the determination of
functional consequence. A total of 13 missense variants were
observed in this cohort: rs45498698, rs144329757, rs999765,
rs569320402, rs62618734, rs147795823, rs149515751,
rs200304246, rs768964879, rs36050417, rs33932471,
2:222347192 and 3:96706703. Four coding variants were considered
functionally consequential for this analysis (Table 2). The synonymous
variant rs7349683 was considered functionally consequential based
on prior literature12,16,19. In the posthoc genotype verification of
rs7349683, sequencing and TaqMan genotyping results were 100%
concordant.
4.2 | Genetic associations with PN sensitivity
The genotype distribution for rs7349683 was consistent with
Hardy–Weinberg equilibrium (minor allele frequency = 0.32,
F IGURE 1 CONSORT diagram of patient
inclusion. One patient received a 3-h paclitaxel
infusion and was excluded. Another patient did
not have a 24-h pharmacokinetic sample
collected, and Tc > 0.05 could not be calculated.
PK = pharmacokinetic; Tc > 0.05 = time above
threshold
TABLE 1 Patient demographic and genetic information
Patient demographics n (%) or mean (standard deviation)
Age (y) 52.52 (10.31)
Body surface area (m2) 1.83 (0.21)
Race (Caucasian) 54 (93.1%)
Tc > 0.05 (h) 10.72 (2.73)
Baseline CIPN8 (range: 0–100) 1.29 (3.04)
Cumulative dose (mg) 883.95 (163.82)
Relative dose intensity 0.95 (0.01)
rs7349683 Heterozygous: 23 (39.7%)
Homozygous variant: 7 (12.1%)




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































P = .51, Table 1). In the PN sensitivity model, which included
Tc > 0.05 and the interaction term, rs7349683 was associated with
greater PN sensitivity (β-coefficient: 0.39, 95% confidence interval
[CI] 0.11–0.67, P = .007, Table 2 and Figure 2A). In a secondary
analysis assuming a dominant genetic effect, rs7349683 was not
associated with PN sensitivity (β-coefficient: 0.35, 95% CI −0.04 to
0.74, P = .08).
Carrying a greater number of missense variants (median = 0,
range 0–2,) was associated with decreased PN sensitivity (β-coeffi-
cient: −0.42, 95% CI −0.72 to −0.12, P = .006, Table 3). The number
of coding (median = 1 range: 0–2) functional variants was not
associated with CIPN8 sensitivity (data not shown).
4.3 | Genetic associations with PN-induced
treatment disruptions
As previously reported, 19 patients experienced at least 1 treatment
disruption during the study11. Neither rs7349683 (odds ratio = 0.46,
95% CI = 0.17–1.26, P = .13) or total missense variants (odds
ratio = 1.04, 95% CI 0.35–3.06, P = .94) were associated with
sensitivity to PN-induced treatment disruption.
4.4 | Posthoc exploration of variants in LD with
rs7349683 and missense variants
Forty-six variants were found to be in LD with rs7349683 using
HaploReg. All variants in LD were located in noncoding or intronic
regions. None of the variants exceeded the thresholds for in silico-
predicted functional consequence (See Methods) of ≥15 for the
CADD PHRED-like scaled C-score rankings. None of the variants
were associated with tissue-specific gene expression in GTex for
neuron-related tissue.
For 4 of the 13 missense variants detected by sequencing,
rs569320402, rs768964879, 2:22347192 and 3:96706703, LD
information was unable to be determined. Ten noncoding or
intronic variants were identified that are in LD with these
remaining 9 missense variants. Two of the missense variants,
rs45498698 and rs144329757, were in complete LD. None of the
variants were associated with neuron-related tissue as determined
by GTex.
4.5 | Posthoc exploration of optimal paclitaxel
exposure by CIPN8 score
Using our final PN model parameters, the Tc > 0.05 that causes a typical
patient to experience several thresholds of CIPN8 during treatment
were estimated. Patients homozygous for rs7349683 have greater
predicted CIPN8 than wild-type or heterozygous patients for Tc > 0.05
(Figure 3). For example, using a threshold of CIPN8 = 30, the optimal
exposure target to reduce PN-related treatment disruption for a
rs7349683 homozygous patient is 11.6 h, whereas the optimal
F IGURE 2 CIPN8 score by cumulative exposure (cumulative dose
* Tc > 0.05) stratified by rs7349683 wild-type, heterozygous and
homozygous patients. Patients homozygous for rs7349683 had a
greater increase in CIPN8 scores with increasing cumulative exposure
than heterozygous and wild-type patientsa. Tc > 0.05 = time above
threshold. aSolid lines represent lines of best fit
TABLE 3 Model containing Tc > 0.05 and rs7349683 or total missense variants
rs7349683 Missense variants
Clinical variable Beta-coefficient (95% CI) P-value Beta-coefficient (95% CI) P-value
Baseline CIPN8 0.20 (0.13–0.26) <.0001 0.20 (0.14–0.27) <.0001
Cumulative dosea −0.12 (−0.55 to 0.31) .57 −0.13 (−0.56–0.31) .56
Dose intensity −1.80 (−3.28 to −0.31) .018 −1.61 (−3.10 to −0.13) .034
Time above threshold −0.29 (−0.51 to −0.07) .011 −0.22 (−0.43 to −0.001) .049
Interaction term with Tc > 0.05 and cumulative dose 0.14 (0.04–0.24) .009 0.14 (0.03–0.25) .009
Genetic variant 0.39 (0.11–0.67) .007 −0.42 (−0.72 to −0.12) .006
aCumulative dose is significant (P < .0001) without the interaction term but is not significant in the model with the interaction, as expected.
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exposure target for a heterozygous or wild-type patient would be
12.6 or 13.6 h, respectively.
5 | DISCUSSION
Paclitaxel-induced PN is a common, debilitating and treatment-limiting
adverse effect that is determined by both paclitaxel exposure and a
patient's predisposition to PN. PN sensitivity is probably influenced
by clinical and genetic factors, such as EPHA variants previously asso-
ciated with increased PN risk12,16,17,19. Using our previously published
PN models that incorporate cumulative paclitaxel treatment and mea-
sured exposure, this proof of concept analysis found evidence that
the EPHA5 synonymous variant rs7349683 is associated with
increased PN sensitivity.
Previous studies have observed associations between variants
in the ephrin (EPHA) genes and increased PN severity or occur-
rence. In genome-wide association studies conducted by Baldwin
et al. and Leandro-Garcia et al., rs7349683 was associated with
lower cumulative dose at the time of National Cancer Institute
Common Terminology Criteria for Adverse Events (NCI-CTCAE)
grade 2 or higher PN occurrence12,19. Additionally, in a candidate
variant study, rs7349683 was found more frequently in PN cases
than controls, as defined by the phenotype extremes using trajec-
tories of CIPN20 increase16. Another candidate variant analysis did
not detect an association for rs7349683 with NCI-CTCAE grade
1 or higher PN20, possibly due to their inability to account for
interpatient variability in paclitaxel exposure or to the use of a
lower PN threshold that is not as accurately classified. The number
of independent studies finding a directionally consistent association
for rs7349683 and increased PN, including ours, diminishes the
likelihood that this is a spurious finding. In our secondary analysis
rs7349683 was not associated with PN-related treatment disrup-
tion, probably due to the modest number of patients experiencing
treatment disruption (n = 19). Patient-reported outcomes are more
sensitive than CTCAE to changes in PN36; however, for a genetic
predictor to be translated into practice it must predict a clinically
relevant endpoint, such as irreversible PN, PN-induced treatment
disruption, PN-related falls or diminished quality of life36,37.
We also unexpectedly found that patients carrying a greater
number of missense variants had lower risk of PN, opposite to a
previous report, where low-frequency missense variants in EPHA5,
EPHA6 and EPHA8 increased PN risk17. EPHA4, EPHA5, EPHA6
and EPHA8 receptors are involved in neural development; how-
ever, pinpointing the precise function of each receptor has been
challenging due to hypothesized partial redundancy in action21
complicating the ability to draw conclusions about the impact of
variants on function. Alternatively, our finding may be a false
positive, as these variants were not found to be in LD with any
putatively consequential variants.
Continued PN biomarker validation is necessary to enable inte-
gration of genetic, clinical and pharmacokinetic data to guide person-
alized paclitaxel therapy. Exposure-guided paclitaxel dosing has been
demonstrated to reduce PN occurrence in nonsmall cell lung cancer
patients receiving paclitaxel every 3 weeks10. However, no prospec-
tive trials have been conducted in patients receiving smaller, weekly
paclitaxel doses, similar to this cohort of patients. If rs7349683 is vali-
dated as a PN sensitivity biomarker, this exposure target would need
to be personalized. Based on the results of this analysis, and assuming
the maximum CIPN8 score a patient can tolerate is 30 based on our
previous findings11, a rs7349683 homozygous subject could only
tolerate a Tc > 0.05 of 12 h whereas carriers or wild-type patients could
tolerate a Tc > 0.05 of 13 and 14 h, respectively. Translation of this
proof of concept personalized exposure-targeted dosing approach
into clinical care will require prospective trials assessing the effect of
rs7349683-guided dosing on PN and efficacy.
Strengths to our approach include the novel inclusion of pacli-
taxel exposure data (Tc > 0.05) in the statistical model to elucidate
EPHA variants associated with PN sensitivity, use of patient
reported outcomes instead of NCI-CTCAE grade, and use of pro-
spectively collected data. In this novel proof of concept analysis,
several limitations are worth considering. These findings may not
be generalizable to other patient populations such as male patients
with breast or other cancer types, or patients treated with other
paclitaxel dosing regimens or other neurotoxic chemotherapeutic
agents. The bioinformatics tools may have incorrectly predicted
which of the variants detected by sequencing are or are not func-
tionally consequential33,38-40. Despite their limitations, the bioinfor-
matics tools have moderate specificity predicting functional
consequence of coding variants41. Noncoding variants were also
assessed using these tools; however, those data were not included
due concerns about the quality of the predictions. Additionally, it
is unclear from our bioinformatics analysis how the synonymous
rs7349683 variant or the combined missense variants impact
F IGURE 3 CIPN8 score by fixed cumulative exposure stratified
by rs7349683 wild-type, heterozygous and homozygous patients.
Maximum tolerated time above threshold (Tc > 0.05) and cumulative
exposure (cumulative dose * Tc > 0.05) was estimated for CIPN8 scores
of 10, 20, 30, and 40. A CIPN8 clinically relevant threshold of 30 is
indicated by dotted lines. Homozygous rs7349683 subjects tolerated
the lowest cumulative exposure and shortest Tc > 0.05. Heterozygous
rs7349683 and wild-type subjects were able to tolerate higher
paclitaxel exposure and longer Tc > 0.05. Tc > 0.05 = time above
threshold
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EPHA5 expression or function, leading to their effects on PN sensi-
tivity. In the missense and coding models, low-frequency variants
were included in the analysis. This assumes that all variants were
similarly consequential to function, which might not be the case.
Another limitation is the lack of statistical correction for the
3 genetic models, increasing the possibility of false positive find-
ings. Despite this fact, the results are significant after multiple
comparisons correction.
Using a novel, sensitive approach for biomarker science that iso-
lates PN sensitivity by accounting for measured systemic paclitaxel
exposure, this study supports prior evidence that EPHA5 rs7349683 is
associated with increased PN, and suggests that this association is
due to its direct effect on increasing PN sensitivity. Additional clinical
pharmacogenetics studies with measured exposure are needed to
confirm the association with clinically meaningful endpoints, followed
by integration of rs7349683 into personalized treatment approaches
and prospective demonstration of improved therapeutic outcomes
from paclitaxel treatment. Finally, researchers should collect drug
exposure data when conducting biomarker studies for multifactorial
toxicities, and use our novel approach of isolating toxicity sensitivity
for biomarker discovery, validation and translation.
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